Previous 10 | Next 10 |
Study Also Shows that Patients’ Decision Regret Levels Do Not Vary According To Low- Or High-Risk DecisionDx-UM Test Result Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatmen...
Castle Biosciences , Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, is a national sponsor of the Colorado Melanoma Foundation, a non-profit organization. Castle will collaborate with the Colora...
The month-long fundraising event invites the public to help log 9,500 miles in honor of the approximately 9,500 people diagnosed with skin cancer every day Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information t...
Myriad Genetics (MYGN) gains 4.4% premarket after signing an agreement to sell the Myriad myPath Melanoma, Laboratory, to Castle Biosciences (CSTL) for $32.5M in cash. Castle Bio is a specialty laboratory focused on advanced diagnostics for dermatologic cancers.“The divestitu...
With the acquisition, Castle expects to make available the most comprehensive molecular testing offering for difficult-to-diagnose melanocytic lesions. The Company to host a conference call today at 7:30 a.m. E.T. Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cance...
Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that it will release its financial results for the first quarter 2021 and provide a pipeline update, after the clo...
The company also presented data on its genomic test for squamous cell carcinoma, DecisionDx-SCC Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, will present data at t...
Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced participation in the Dermatology Nurses’ Association 2021 Annual Convention. Castle presented posters highl...
Castle highlights its suite of skin cancer genomic tests Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, presented data on its three skin cancer gene expression profi...
i31-GEP integrates DecisionDx-Melanoma continuous score with clinicopathologic factors designed to provide a more precise, personalized likelihood of sentinel lymph node positivity Castle Biosciences , Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing pers...
News, Short Squeeze, Breakout and More Instantly...
Castle Biosciences Inc. Company Name:
CSTL Stock Symbol:
NASDAQ Market:
Castle Biosciences Inc. Website:
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Canaccord Genuity 44 th Annual Growth Conference on Tuesday, Aug. 13, 2024, at ...
Campaign will focus on empowering patients impacted by melanoma Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, has joined forces with television personality, wellness coach and founder of ALL IN by Teddi, host of the...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter and six months ended June 30, 2024, after the close of market on Monday, Aug. 5, 2024. Compan...